BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brouwer KL, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, Meibohm B, Nigam SK, Rieder M, de Wildt SN; Pediatric Transporter Working Group. Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group. Clin Pharmacol Ther 2015;98:266-87. [PMID: 26088472 DOI: 10.1002/cpt.176] [Cited by in Crossref: 113] [Cited by in F6Publishing: 91] [Article Influence: 16.1] [Reference Citation Analysis]
Number Citing Articles
1 Rodieux F, Vutskits L, Posfay-Barbe KM, Habre W, Piguet V, Desmeules JA, Samer CF. When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children. Front Pharmacol 2018;9:148. [PMID: 29556194 DOI: 10.3389/fphar.2018.00148] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
2 Rieder M. Pharmacy and pediatric drug therapy: The key to safe and effective treatment for children. Am J Health Syst Pharm 2019;76:1452-3. [PMID: 31532499 DOI: 10.1093/ajhp/zxz171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 van Groen BD, Nicolaï J, Kuik AC, Van Cruchten S, van Peer E, Smits A, Schmidt S, de Wildt SN, Allegaert K, De Schaepdrijver L, Annaert P, Badée J. Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species. Pharmacol Rev 2021;73:597-678. [PMID: 33608409 DOI: 10.1124/pharmrev.120.000071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
4 Caetano-pinto P, Jansen J, Assaraf YG, Masereeuw R. The importance of breast cancer resistance protein to the kidneys excretory function and chemotherapeutic resistance. Drug Resistance Updates 2017;30:15-27. [DOI: 10.1016/j.drup.2017.01.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
5 Thomson MM, Hines RN, Schuetz EG, Meibohm B. Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver. Drug Metab Dispos 2016;44:999-1004. [PMID: 27098745 DOI: 10.1124/dmd.115.069252] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
6 Rieder M. Adverse Drug Reactions Across the Age Continuum: Epidemiology, Diagnostic Challenges, Prevention, and Treatments. J Clin Pharmacol 2018;58 Suppl 10:S36-47. [PMID: 30248196 DOI: 10.1002/jcph.1115] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
7 Rieder M. Size and Taste Matters: Recent Progress in the Development of Age-Appropriate Medicines for Children. Pharm Med 2018;32:21-30. [DOI: 10.1007/s40290-017-0218-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
8 Elmorsi Y, Barber J, Rostami-hodjegan A. Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics. Drug Metabolism and Disposition 2016;44:992-8. [DOI: 10.1124/dmd.115.067801] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
9 Mooij MG, van de Steeg E, van Rosmalen J, Windster JD, de Koning BA, Vaes WH, van Groen BD, Tibboel D, Wortelboer HM, de Wildt SN. Proteomic Analysis of the Developmental Trajectory of Human Hepatic Membrane Transporter Proteins in the First Three Months of Life. Drug Metab Dispos 2016;44:1005-13. [PMID: 27103634 DOI: 10.1124/dmd.115.068577] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
10 Ayuso M, Buyssens L, Stroe M, Valenzuela A, Allegaert K, Smits A, Annaert P, Mulder A, Carpentier S, Van Ginneken C, Van Cruchten S. The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development. Pharmaceutics 2020;13:44. [PMID: 33396805 DOI: 10.3390/pharmaceutics13010044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Verscheijden LFM, van Hattem AC, Pertijs JCLM, de Jongh CA, Verdijk RM, Smeets B, Koenderink JB, Russel FGM, de Wildt SN. Developmental patterns in human blood-brain barrier and blood-cerebrospinal fluid barrier ABC drug transporter expression. Histochem Cell Biol 2020;154:265-73. [PMID: 32448916 DOI: 10.1007/s00418-020-01884-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
12 Momper JD, Nigam SK. Developmental regulation of kidney and liver solute carrier and ATP-binding cassette drug transporters and drug metabolizing enzymes: the role of remote organ communication. Expert Opin Drug Metab Toxicol 2018;14:561-70. [PMID: 29746174 DOI: 10.1080/17425255.2018.1473376] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
13 Cheung KWK, van Groen BD, Spaans E, van Borselen MD, de Bruijn ACJM, Simons-Oosterhuis Y, Tibboel D, Samsom JN, Verdijk RM, Smeets B, Zhang L, Huang SM, Giacomini KM, de Wildt SN. A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization. Clin Pharmacol Ther 2019;106:1083-92. [PMID: 31127606 DOI: 10.1002/cpt.1516] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
14 Prasad B, Gaedigk A, Vrana M, Gaedigk R, Leeder JS, Salphati L, Chu X, Xiao G, Hop C, Evers R, Gan L, Unadkat JD. Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics. Clin Pharmacol Ther 2016;100:362-70. [PMID: 27301780 DOI: 10.1002/cpt.409] [Cited by in Crossref: 84] [Cited by in F6Publishing: 75] [Article Influence: 14.0] [Reference Citation Analysis]
15 Mlakar V, Huezo-Diaz Curtis P, Satyanarayana Uppugunduri CR, Krajinovic M, Ansari M. Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. Int J Mol Sci 2016;17:E1502. [PMID: 27618021 DOI: 10.3390/ijms17091502] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
16 Shakhnovich V, Hornik CP, Kearns GL, Weigel J, Abdel-Rahman SM. How to Conduct Clinical Trials in Children: A Tutorial. Clin Transl Sci 2019;12:218-30. [PMID: 30657253 DOI: 10.1111/cts.12615] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
17 van Groen BD, van de Steeg E, Mooij MG, van Lipzig MMH, de Koning BAE, Verdijk RM, Wortelboer HM, Gaedigk R, Bi C, Leeder JS, van Schaik RHN, van Rosmalen J, Tibboel D, Vaes WH, de Wildt SN. Proteomics of human liver membrane transporters: a focus on fetuses and newborn infants. Eur J Pharm Sci 2018;124:217-27. [PMID: 30171984 DOI: 10.1016/j.ejps.2018.08.042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
18 Naji-Talakar S, Sharma S, Martin LA, Barnhart D, Prasad B. Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units. Expert Opin Drug Metab Toxicol 2021;17:273-89. [PMID: 33256492 DOI: 10.1080/17425255.2021.1858051] [Reference Citation Analysis]
19 Ince I, Solodenko J, Frechen S, Dallmann A, Niederalt C, Schlender J, Burghaus R, Lippert J, Willmann S. Predictive Pediatric Modeling and Simulation Using Ontogeny Information. J Clin Pharmacol 2019;59 Suppl 1:S95-S103. [PMID: 31502689 DOI: 10.1002/jcph.1497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Vinarov Z, Abrahamsson B, Artursson P, Batchelor H, Berben P, Bernkop-Schnürch A, Butler J, Ceulemans J, Davies N, Dupont D, Flaten GE, Fotaki N, Griffin BT, Jannin V, Keemink J, Kesisoglou F, Koziolek M, Kuentz M, Mackie A, Meléndez-Martínez AJ, McAllister M, Müllertz A, O'Driscoll CM, Parrott N, Paszkowska J, Pavek P, Porter CJH, Reppas C, Stillhart C, Sugano K, Toader E, Valentová K, Vertzoni M, De Wildt SN, Wilson CG, Augustijns P. Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Adv Drug Deliv Rev 2021;171:289-331. [PMID: 33610694 DOI: 10.1016/j.addr.2021.02.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
21 Mooij MG, de Koning BE, Lindenbergh-Kortleve DJ, Simons-Oosterhuis Y, van Groen BD, Tibboel D, Samsom JN, de Wildt SN. Human Intestinal PEPT1 Transporter Expression and Localization in Preterm and Term Infants. Drug Metab Dispos 2016;44:1014-9. [PMID: 27079248 DOI: 10.1124/dmd.115.068809] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
22 Haga SB. Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges. Pharmgenomics Pers Med 2019;12:273-85. [PMID: 31686893 DOI: 10.2147/PGPM.S179172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Al-Khouja A, Park K, Anderson DJC, Young C, Wang J, Huang SM, Khurana M, Burckart GJ. Dosing Recommendations for Pediatric Patients With Renal Impairment. J Clin Pharmacol 2020;60:1551-60. [PMID: 32542790 DOI: 10.1002/jcph.1676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Adam de Beaumais T, Jacqz-Aigrain E. Pharmacogenetics: Applications to Pediatric Patients. Adv Pharmacol 2018;83:191-215. [PMID: 29801575 DOI: 10.1016/bs.apha.2018.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Dallmann A, Liu XI, Burckart GJ, van den Anker J. Drug Transporters Expressed in the Human Placenta and Models for Studying Maternal-Fetal Drug Transfer. J Clin Pharmacol 2019;59 Suppl 1:S70-81. [PMID: 31502693 DOI: 10.1002/jcph.1491] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
26 Eidelman C, Abdel-rahman SM. Pharmacokinetic considerations when prescribing in children. International Journal of Pharmacokinetics 2016;1:69-80. [DOI: 10.4155/ipk-2016-0001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Hahn D, Emoto C, Vinks AA, Fukuda T. Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children. Drug Metab Dispos 2017;45:23-6. [PMID: 27780835 DOI: 10.1124/dmd.116.072256] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
28 Lavan M, Byrn SR, Knipp G. Pediatric Formulations: Knowledge Gaps Limiting the Expedited Preclinical to Clinical Translation in Children. AAPS PharmSciTech 2019;20:73. [PMID: 30631973 DOI: 10.1208/s12249-018-1253-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
29 Howard M, Barber J, Alizai N, Rostami-Hodjegan A. Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics. Expert Opin Drug Metab Toxicol 2018;14:1315-30. [PMID: 30465453 DOI: 10.1080/17425255.2018.1546288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
30 Nicolas JM, de Lange ECM. Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity. AAPS J 2019;21:67. [PMID: 31140038 DOI: 10.1208/s12248-019-0340-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
31 Guimarães M, Statelova M, Holm R, Reppas C, Symilllides M, Vertzoni M, Fotaki N. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products - a PEARRL review. J Pharm Pharmacol 2019;71:603-42. [PMID: 29971768 DOI: 10.1111/jphp.12955] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
32 van Groen BD, van Duijn E, de Vries A, Mooij MG, Tibboel D, Vaes WHJ, de Wildt SN. Proof of Concept: First Pediatric [14 C]microtracer Study to Create Metabolite Profiles of Midazolam. Clin Pharmacol Ther 2020;108:1003-9. [PMID: 32386327 DOI: 10.1002/cpt.1884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Wang X, Lou K, Song X, Ma H, Zhou X, Xu H, Wang W. Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells. Toxicol Appl Pharmacol 2020;396:115001. [PMID: 32277947 DOI: 10.1016/j.taap.2020.115001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Li CY, Basit A, Gupta A, Gáborik Z, Kis E, Prasad B. Major glucuronide metabolites of testosterone are primarily transported by MRP2 and MRP3 in human liver, intestine and kidney. J Steroid Biochem Mol Biol 2019;191:105350. [PMID: 30959153 DOI: 10.1016/j.jsbmb.2019.03.027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
35 Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck D, Bresson JL, Dusemund B, Gundert-Remy U, Kersting M, Lambré C, Penninks A, Tritscher A, Waalkens-Berendsen I, Woutersen R, Arcella D, Court Marques D, Dorne JL, Kass GE, Mortensen A; EFSA Scientific Committee. Guidance on the risk assessment of substances present in food intended for infants below 16 weeks of age. EFSA J 2017;15:e04849. [PMID: 32625502 DOI: 10.2903/j.efsa.2017.4849] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 8.2] [Reference Citation Analysis]
36 Thigpen JC, Odle BL, Harirforoosh S. Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. Eur J Drug Metab Pharmacokinet 2019;44:591-609. [PMID: 31006834 DOI: 10.1007/s13318-019-00552-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 11.5] [Reference Citation Analysis]
37 Guo Y, Chu X, Parrott NJ, Brouwer KLR, Hsu V, Nagar S, Matsson P, Sharma P, Snoeys J, Sugiyama Y, Tatosian D, Unadkat JD, Huang SM, Galetin A; International Transporter Consortium. Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clin Pharmacol Ther 2018;104:865-89. [PMID: 30059145 DOI: 10.1002/cpt.1183] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 15.5] [Reference Citation Analysis]
38 Rioux N, Waters NJ. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development. Drug Metabolism and Disposition 2016;44:934-43. [DOI: 10.1124/dmd.115.068031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
39 Hagos FT, Adams SM, Poloyac SM, Kochanek PM, Horvat CM, Clark RSB, Empey PE. Membrane transporters in traumatic brain injury: Pathological, pharmacotherapeutic, and developmental implications. Exp Neurol 2019;317:10-21. [PMID: 30797827 DOI: 10.1016/j.expneurol.2019.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kimoto E, Obach RS, Varma MV. Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions. Drug Metabolism and Pharmacokinetics 2020;35:18-29. [DOI: 10.1016/j.dmpk.2019.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Bueters R, Bael A, Gasthuys E, Chen C, Schreuder MF, Frazier KS. Ontogeny and Cross-species Comparison of Pathways Involved in Drug Absorption, Distribution, Metabolism, and Excretion in Neonates (Review): Kidney. Drug Metab Dispos 2020;48:353-67. [DOI: 10.1124/dmd.119.089755] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
42 Nicklisch SCT, Hamdoun A. Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs). FEBS Lett 2020;594:4158-85. [PMID: 33222203 DOI: 10.1002/1873-3468.14005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Neal-kluever A, Fisher J, Grylack L, Kakiuchi-kiyota S, Halpern W. Physiology of the Neonatal Gastrointestinal System Relevant to the Disposition of Orally Administered Medications. Drug Metab Dispos 2019;47:296-313. [DOI: 10.1124/dmd.118.084418] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
44 Leeder JS, Meibohm B. Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development. Drug Metab Dispos 2016;44:916-23. [PMID: 27302933 DOI: 10.1124/dmd.116.071159] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
45 Chapron BD, Chapron A, Leeder JS. Recent advances in the ontogeny of drug disposition. Br J Clin Pharmacol 2021. [PMID: 33733546 DOI: 10.1111/bcp.14821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
46 Stillhart C, Vučićević K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, Gesquiere I, Greupink R, Keszthelyi D, Koskinen M, Madla CM, Matthys C, Miljuš G, Mooij MG, Parrott N, Ungell A, de Wildt SN, Orlu M, Klein S, Müllertz A. Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review. European Journal of Pharmaceutical Sciences 2020;147:105280. [DOI: 10.1016/j.ejps.2020.105280] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 18.5] [Reference Citation Analysis]
47 Govindarajan R, Sparreboom A. Drug Transporters: Advances and Opportunities. Clin Pharmacol Ther 2016;100:398-403. [PMID: 27718234 DOI: 10.1002/cpt.454] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
48 Cheung KWK, van Groen BD, Burckart GJ, Zhang L, de Wildt SN, Huang SM. Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters. J Clin Pharmacol 2019;59 Suppl 1:S56-69. [PMID: 31502692 DOI: 10.1002/jcph.1489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
49 Prasad B, Vrana M, Mehrotra A, Johnson K, Bhatt DK. The Promises of Quantitative Proteomics in Precision Medicine. J Pharm Sci 2017;106:738-44. [PMID: 27939376 DOI: 10.1016/j.xphs.2016.11.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
50 Neuhoff S, Harwood MD, Rostami-Hodjegan A, Achour B. Application of proteomic data in the translation of in vitro observations to associated clinical outcomes. Drug Discov Today Technol 2021;39:13-22. [PMID: 34906322 DOI: 10.1016/j.ddtec.2021.06.002] [Reference Citation Analysis]
51 Shi Q, Yang X, Greenhaw JJ, Salminen AT, Russotti GM, Salminen WF. Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status. Int J Toxicol 2017;36:365-79. [PMID: 28820004 DOI: 10.1177/1091581817721675] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
52 Shawahna R. Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume. AAPS J 2016;18:728-36. [PMID: 26935428 DOI: 10.1208/s12248-016-9885-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
53 Lin W, Yan J, Heimbach T, He H. Pediatric Physiologically Based Pharmacokinetic Model Development: Current Status and Challenges. Curr Pharmacol Rep 2018;4:491-501. [DOI: 10.1007/s40495-018-0162-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
54 Neyro V, Elie V, Médard Y, Jacqz-aigrain E. mRNA expression of drug metabolism enzymes and transporter genes at birth using human umbilical cord blood. Fundam Clin Pharmacol 2018;32:422-35. [DOI: 10.1111/fcp.12357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Kölz C, Schaeffeler E, Schwab M, Nies AT. Genetic and Epigenetic Regulation of Organic Cation Transporters. Berlin: Springer Berlin Heidelberg; 2021. [DOI: 10.1007/164_2021_450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Kulkarni PR, Youssef AS, Argikar AA. Prediction of Drug Clearance from Enzyme and Transporter Kinetics. Methods Mol Biol 2021;2342:369-417. [PMID: 34272702 DOI: 10.1007/978-1-0716-1554-6_14] [Reference Citation Analysis]
57 Frazier KS. The Impact of Functional and Structural Maturation of the Kidney on Susceptibility to Drug and Chemical Toxicity in Neonatal Rodents. Toxicol Pathol 2021;:1926233211035683. [PMID: 34338059 DOI: 10.1177/01926233211035683] [Reference Citation Analysis]
58 Waalewijn H, Turkova A, Rakhmanina N, Cressey TR, Penazzato M, Colbers A, Burger DM; Pediatric Antiretroviral Working Group (PAWG). Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV. Ther Drug Monit 2019;41:431-43. [PMID: 31008997 DOI: 10.1097/FTD.0000000000000637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
59 Mayinda GD, Serreau D, Gesbert A, Reigner F, Sutra JF, Lespine A, Sallé G. Ivermectin treatment in lactating mares results in suboptimal ivermectin exposure in their suckling foals. Vet Parasitol 2021;296:109511. [PMID: 34237517 DOI: 10.1016/j.vetpar.2021.109511] [Reference Citation Analysis]
60 Smeets NJL, Litjens CHC, van den Heuvel JJMW, van Hove H, van den Broek P, Russel FGM, Koenderink JB, de Wildt SN. Completing the Enalaprilat Excretion Pathway-Renal Handling by the Proximal Tubule. Pharmaceutics 2020;12:E935. [PMID: 33007874 DOI: 10.3390/pharmaceutics12100935] [Reference Citation Analysis]
61 McPhail BT, Emoto C, Butler D, Fukuda T, Akinbi H, Vinks AA. Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches. J Clin Pharmacol 2021;61:857-70. [PMID: 33382111 DOI: 10.1002/jcph.1811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Veal GJ, Errington J, Sastry J, Chisholm J, Brock P, Morgenstern D, Pritchard-Jones K, Chowdhury T. Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens. Cancer Chemother Pharmacol 2016;77:685-92. [PMID: 26875154 DOI: 10.1007/s00280-016-2975-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
63 Rodieux F, Gotta V, Pfister M, van den Anker JN. Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy. J Clin Pharmacol 2016;56 Suppl 7:S173-92. [PMID: 27385174 DOI: 10.1002/jcph.721] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
64 Nigam SK. The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease. Annu Rev Pharmacol Toxicol. 2018;58:663-687. [PMID: 29309257 DOI: 10.1146/annurev-pharmtox-010617-052713] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 24.7] [Reference Citation Analysis]
65 Schijvens AM, de Wildt SN, Schreuder MF. Pharmacokinetics in children with chronic kidney disease. Pediatr Nephrol 2020;35:1153-72. [PMID: 31375913 DOI: 10.1007/s00467-019-04304-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 van Groen BD, Bi C, Gaedigk R, Staggs VS, Tibboel D, de Wildt SN, Leeder JS. Alternative Splicing of the SLCO1B1 Gene: An Exploratory Analysis of Isoform Diversity in Pediatric Liver. Clin Transl Sci 2020;13:509-19. [PMID: 31917523 DOI: 10.1111/cts.12733] [Reference Citation Analysis]
67 McLaughlin MJ, Wagner J, Shakhnovich V, Carleton B, Leeder JS. Considerations for Implementing Precision Therapeutics for Children. Clin Transl Sci 2019;12:140-50. [PMID: 30516322 DOI: 10.1111/cts.12607] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
68 Momper JD, Yang J, Gockenbach M, Vaida F, Nigam SK. Dynamics of Organic Anion Transporter-Mediated Tubular Secretion during Postnatal Human Kidney Development and Maturation. Clin J Am Soc Nephrol 2019;14:540-8. [PMID: 30885911 DOI: 10.2215/CJN.10350818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
69 Rafaniello C, Sessa M, Bernardi FF, Pozzi M, Cheli S, Cattaneo D, Baldelli S, Molteni M, Bernardini R, Rossi F, Clementi E, Bravaccio C, Radice S, Capuano A. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J 2018;18:422-30. [PMID: 28719598 DOI: 10.1038/tpj.2017.38] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
70 Nies AT, Damme K, Kruck S, Schaeffeler E, Schwab M. Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. Arch Toxicol 2016;90:1555-84. [PMID: 27165417 DOI: 10.1007/s00204-016-1728-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
71 Bhatt-Mehta V, Hammoud H, Amidon GL. A proposed pediatric biopharmaceutical classification system for medications for chronic diseases in children. Eur J Pharm Sci 2020;152:105437. [PMID: 32598914 DOI: 10.1016/j.ejps.2020.105437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Matic M, de Wildt SN, Elens L, de Hoon JN, Annaert P, Tibboel D, van Schaik RH, Allegaert K. SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants. Ther Drug Monit 2016;38:487-92. [PMID: 27082504 DOI: 10.1097/FTD.0000000000000307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 2.4] [Reference Citation Analysis]
73 Euteneuer JC, Kamatkar S, Fukuda T, Vinks AA, Akinbi HT. Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy. J Clin Pharmacol 2019;59:168-76. [PMID: 30204236 DOI: 10.1002/jcph.1315] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
74 Mooij MG, Nies AT, Knibbe CA, Schaeffeler E, Tibboel D, Schwab M, de Wildt SN. Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clin Pharmacokinet 2016;55:507-24. [PMID: 26410689 DOI: 10.1007/s40262-015-0328-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
75 Elder DP, Holm R, Kuentz M. Medicines for Pediatric Patients-Biopharmaceutical, Developmental, and Regulatory Considerations. J Pharm Sci 2017;106:950-60. [PMID: 28041968 DOI: 10.1016/j.xphs.2016.12.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
76 Cristea S, Krekels EHJ, Allegaert K, De Paepe P, de Jaeger A, De Cock P, Knibbe CAJ. Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3. AAPS J 2021;23:65. [PMID: 33948771 DOI: 10.1208/s12248-021-00595-9] [Reference Citation Analysis]
77 Kelly LE, Sinha Y, Barker CIS, Standing JF, Offringa M. Useful pharmacodynamic endpoints in children: selection, measurement, and next steps. Pediatr Res 2018;83:1095-103. [PMID: 29667952 DOI: 10.1038/pr.2018.38] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
78 Emoto C, Fukuda T, Johnson TN, Neuhoff S, Sadhasivam S, Vinks AA. Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter. CPT Pharmacometrics Syst Pharmacol 2017;6:110-9. [PMID: 27935268 DOI: 10.1002/psp4.12144] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
79 Weyrich A, Frericks M, Eichenlaub M, Schneider S, Hofmann T, Van Cruchten S, van Ravenzwaay B. Ontogeny of renal, hepatic, and placental expression of ATP-binding cassette and solute carrier transporters in the rat and the rabbit. Reprod Toxicol 2021;107:1-9. [PMID: 34757165 DOI: 10.1016/j.reprotox.2021.10.005] [Reference Citation Analysis]
80 Smits A, De Cock P, Vermeulen A, Allegaert K. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute. Expert Opin Drug Metab Toxicol 2019;15:25-34. [PMID: 30554542 DOI: 10.1080/17425255.2019.1558205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
81 Vinks AA, Emoto C, Fukuda T. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children. Clin Pharmacol Ther. 2015;98:298-308. [PMID: 26073179 DOI: 10.1002/cpt.169] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
82 Burris JF, Tortorici MA, Mandic M, Neely M, Reed MD. Dosage Adjustments Related to Young or Old Age and Organ Impairment. J Clin Pharmacol 2016;56:1461-73. [PMID: 27539787 DOI: 10.1002/jcph.816] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
83 Cuzzolin L, Oggiano AM, Clemente MG, Locci C, Antonucci L, Antonucci R. Ceftriaxone-associated biliary pseudolithiasis in children: do we know enough? Fundam Clin Pharmacol. 2021;35:40-52. [PMID: 32492204 DOI: 10.1111/fcp.12577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
84 Matic M, de Wildt SN, Tibboel D, van Schaik RHN. Analgesia and Opioids: A Pharmacogenetics Shortlist for Implementation in Clinical Practice. Clinical Chemistry 2017;63:1204-13. [DOI: 10.1373/clinchem.2016.264986] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
85 Eke AC. An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics. J Basic Clin Physiol Pharmacol 2021. [PMID: 34881531 DOI: 10.1515/jbcpp-2021-0312] [Reference Citation Analysis]
86 Rieder M, Hawcutt D. Design and conduct of early phase drug studies in children: challenges and opportunities. Br J Clin Pharmacol 2016;82:1308-14. [PMID: 27353241 DOI: 10.1111/bcp.13058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
87 van Groen BD, Pilla Reddy V, Badée J, Olivares-Morales A, Johnson TN, Nicolaï J, Annaert P, Smits A, de Wildt SN, Knibbe CAJ, de Zwart L. Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium. Clin Transl Sci 2021;14:29-35. [PMID: 32702198 DOI: 10.1111/cts.12843] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
88 Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, Montealegre Sanchez GA, de Jesus AA, Huang Y, Tsai WL, Gadina M, Prakash A, Janes JM, Zhang X, Macias WL, Kumar P, Goldbach-Mansky R. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. Clin Pharmacol Ther 2018;104:364-73. [PMID: 29134648 DOI: 10.1002/cpt.936] [Cited by in F6Publishing: 37] [Reference Citation Analysis]
89 Wollmer E, Ungell AL, Nicolas JM, Klein S. Review of paediatric gastrointestinal physiology relevant to the absorption of orally administered medicines. Adv Drug Deliv Rev 2021;:114084. [PMID: 34929252 DOI: 10.1016/j.addr.2021.114084] [Reference Citation Analysis]
90 McPhail BT, Emoto C, Fukuda T, Butler D, Wiles JR, Akinbi H, Vinks AA. Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients. J Clin Pharmacol 2020;60:453-65. [PMID: 31820437 DOI: 10.1002/jcph.1538] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
91 Thomas M, Hardikar W, Greaves RF, Tingay DG, Loh TP, Ignjatovic V, Newall F, Rajapaksa AE. Mechanism of bilirubin elimination in urine: insights and prospects for neonatal jaundice. Clin Chem Lab Med 2021;59:1025-33. [PMID: 33554547 DOI: 10.1515/cclm-2020-1759] [Reference Citation Analysis]
92 Li CY, Hosey-Cojocari C, Basit A, Unadkat JD, Leeder JS, Prasad B. Optimized Renal Transporter Quantification by Using Aquaporin 1 and Aquaporin 2 as Anatomical Markers: Application in Characterizing the Ontogeny of Renal Transporters and Its Correlation with Hepatic Transporters in Paired Human Samples. AAPS J 2019;21:88. [PMID: 31297641 DOI: 10.1208/s12248-019-0359-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
93 Scotcher D, Jones C, Posada M, Rostami-Hodjegan A, Galetin A. Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data. AAPS J 2016;18:1067-81. [PMID: 27365096 DOI: 10.1208/s12248-016-9942-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
94 Germovsek E, Barker CIS, Sharland M, Standing JF. Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. Clin Pharmacokinet 2019;58:39-52. [PMID: 29675639 DOI: 10.1007/s40262-018-0659-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
95 Fisel P, Schaeffeler E, Schwab M. DNA Methylation of ADME Genes. Clin Pharmacol Ther 2016;99:512-27. [PMID: 27061006 DOI: 10.1002/cpt.343] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
96 Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther 2016;99:651-60. [PMID: 26663398 DOI: 10.1002/cpt.315] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]